Hemolytic Anemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HML002 MIFTS: 64	Hemolytic Anemia Categories: Blood diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Hemolytic Anemia

MalaCards integrated aliases for Hemolytic Anemia:

Name: Hemolytic Anemia ³⁹ ¹² ³⁰ ⁶ ¹⁵ ⁶⁴ ¹⁷

Anemia, Hemolytic ⁴⁵ ⁴¹ ⁷⁴

Anemia Hemolytic ¹² ⁵⁶

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases Genetic diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

Haemolytic anaemias

External Ids:

Disease Ontology ¹² DOID:583

MeSH ⁴⁵ D000743

NCIt ⁵¹ C34376

SNOMED-CT ⁶⁹ 61261009

ICD10 ³⁴ D55-D59

EFO ¹⁷ EFO_0005558

UMLS ⁷⁴ C0002878

Sources

Summaries for Hemolytic Anemia

PubMed Health : ⁶⁴ About hemolytic anemia: Hemolytic anemia (HEE-moh-lit-ick uh-NEE-me-uh) is a condition in which red blood cells are destroyed and removed from the bloodstream before their normal lifespan is over.Red blood cells are disc-shaped and look like doughnuts without holes in the center. These cells carry oxygen to your body. They also remove carbon dioxide (a waste product) from your body.Red blood cells are made in the bone marrow—a sponge-like tissue inside the bones. They live for about 120 days in the bloodstream and then die.White blood cells and platelets (PLATE-lets) also are made in the bone marrow. White blood cells help fight infections. Platelets stick together to seal small cuts or breaks on blood vessel walls and stop bleeding.When blood cells die, the body's bone marrow makes more blood cells to replace them. However, in hemolytic anemia, the bone marrow can't make red blood cells fast enough to meet the body's needs.Hemolytic anemia can lead to many health problems, such as fatigue (tiredness), pain, irregular heartbeats called arrhythmias (ah-RITH-me-ahs), an enlarged heart, and heart failure.

MalaCards based summary : Hemolytic Anemia, also known as anemia, hemolytic, is related to congenital nonspherocytic hemolytic anemia and pyruvate kinase deficiency of red cells, and has symptoms including icterus An important gene associated with Hemolytic Anemia is SPTB (Spectrin Beta, Erythrocytic), and among its related pathways/superpathways are Metabolism and Glycosaminoglycan metabolism. The drugs Iron and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are no effect and Increased simian virus 40 (SV40) infection

Wikipedia : ⁷⁷ Hemolytic anemia is a form of anemia due to hemolysis, the abnormal breakdown of red blood cells (RBCs),... more...

Sources

Related Diseases for Hemolytic Anemia

Diseases in the Hemolytic Anemia family:

Anemia, Autoimmune Hemolytic	Congenital Hemolytic Anemia
Hemolytic Anemia Due to Erythrocyte Adenosine Deaminase Overproduction

Diseases related to Hemolytic Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 627)

#	Related Disease	Score	Top Affiliating Genes
1	congenital nonspherocytic hemolytic anemia	34.2	G6PD GPI NT5C3A PKLR
2	pyruvate kinase deficiency of red cells	34.0	G6PD PKLR
3	congenital hemolytic anemia	33.9	ANK1 G6PD GPI HBB PKLR SPTA1
4	hereditary spherocytosis	33.1	ANK1 EPB42 G6PD HBB PKLR SLC4A1
5	glucosephosphate dehydrogenase deficiency	33.0	G6PD HBB
6	pyropoikilocytosis, hereditary	33.0	SPTA1 SPTB
7	glucosephosphate isomerase deficiency	32.8	G6PD GPI
8	spherocytosis, type 3	32.6	HBB SPTA1
9	glutathione synthetase deficiency	32.6	G6PD GSS
10	beta-thalassemia	30.5	G6PD HBB SPTB
11	hereditary elliptocytosis	30.5	ANK1 SLC4A1 SPTA1 SPTB
12	malaria	30.4	ADAMTS13 G6PD HBB PKLR SLC4A1
13	kernicterus	30.0	G6PD SLC4A1
14	hemolytic anemia, nonspherocytic, due to hexokinase deficiency	12.7
15	uridine 5-prime monophosphate hydrolase deficiency, hemolytic anemia due to	12.7
16	gamma-glutamylcysteine synthetase deficiency, hemolytic anemia due to	12.7
17	adenylate kinase deficiency, hemolytic anemia due to	12.7
18	warm antibody hemolytic anemia	12.6
19	hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency	12.6
20	renal tubular acidosis, distal, with hemolytic anemia	12.6
21	drug-induced autoimmune hemolytic anemia	12.5
22	glutathione synthetase deficiency of erythrocytes, hemolytic anemia due to	12.5
23	hemolytic anemia, congenital, x-linked	12.5
24	hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy	12.5
25	anemia, autoimmune hemolytic	12.5
26	mixed-type autoimmune hemolytic anemia	12.3
27	systemic lupus erythematosus with hemolytic anemia 1	12.3
28	autoimmune hemolytic anemia, warm type	12.3
29	thrombotic thrombocytopenic purpura, congenital	12.3
30	hemolytic anemia, lethal congenital nonspherocytic, with genital and other abnormalities	12.3
31	adenosine deaminase, elevated, hemolytic anemia due to	12.2
32	hemolytic anemia with thermal sensitivity of red cells	12.2
33	glut1 deficiency syndrome 2	12.2
34	triosephosphate isomerase deficiency	12.2
35	lymphopenic hypergammaglobulinemia, antibody deficiency, autoimmune hemolytic anemia, and glomerulonephritis	12.1
36	neonatal autoimmune hemolytic anemia	12.1
37	autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome	12.1
38	hemolytic anemia due to glutathione reductase deficiency	12.1
39	hemolytic anemia due to erythrocyte adenosine deaminase overproduction	12.1
40	anemia, nonspherocytic hemolytic, due to g6pd deficiency	12.1
41	paroxysmal cold hemoglobinuria	12.1
42	immunodysregulation, polyendocrinopathy, and enteropathy, x-linked	12.0
43	evans' syndrome	12.0
44	glucose phosphate isomerase deficiency	12.0
45	glutathione peroxidase deficiency	12.0
46	cold agglutinin disease	12.0
47	hemolytic-uremic syndrome	11.9
48	rh-null, regulator type	11.9
49	phosphoglycerate kinase deficiency	11.8
50	dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema	11.8

Graphical network of the top 20 diseases related to Hemolytic Anemia:

Sources

Symptoms & Phenotypes for Hemolytic Anemia

UMLS symptoms related to Hemolytic Anemia:

icterus

GenomeRNAi Phenotypes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

²⁷

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	9.92	ADAMTS13 AK1 ALDOA ANK1 CD59 EPB42
2	Increased simian virus 40 (SV40) infection	GR00356-A-2	9.13	HK1 PGK1 PKLR

MGI Mouse Phenotypes related to Hemolytic Anemia:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	hematopoietic system	MP:0005397	9.97	ADAMTS13 ANK1 CD59 EPB42 G6PD GPI
2	homeostasis/metabolism	MP:0005376	9.8	ADAMTS13 AK1 ANK1 CD59 EPB42 G6PD
3	mortality/aging	MP:0010768	9.4	ADAMTS13 ANK1 CD59 G6PD GCLC GPI

Sources

Drugs & Therapeutics for Hemolytic Anemia

PubMedHealth treatment related to Hemolytic Anemia: ⁶⁴

Treatments for hemolytic anemia include blood transfusions, medicines, plasmapheresis (PLAZ-meh-feh-RE-sis), surgery, blood and marrow stem cell transplants, and lifestyle changes.People who have mild hemolytic anemia may not need treatment, as long as the condition doesn't worsen. People who have severe hemolytic anemia usually need ongoing treatment. Severe hemolytic anemia can be fatal if it's not properly treated.

Drugs for Hemolytic Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 525)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Iron

Approved, Experimental

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

7439-89-6, 15438-31-0

27284 23925

Omeprazole

Approved, Investigational, Vet_approved

Phase 4,Phase 1

73590-58-6

4594

Hydroxyurea

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

127-07-1

3657

Deferiprone

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

30652-11-0

2972

Deferoxamine

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

70-51-9

2973

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

22916-47-8

4189

Basiliximab

Approved, Investigational

Phase 4,Phase 2

179045-86-4, 152923-56-3

Mycophenolic acid

Approved

Phase 4,Phase 2,Phase 1,Not Applicable

24280-93-1

446541

Methotrexate

Approved

Phase 4,Phase 3,Phase 2,Phase 1

1959-05-2, 59-05-2

126941

leucovorin

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

58-05-9

143 6006

Nitric Oxide

Approved

Phase 4,Phase 2,Phase 3,Phase 1

10102-43-9

145068

Morphine

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

57-27-2

5288826

Deferasirox

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

201530-41-8

5493381

Zoledronic Acid

Approved

Phase 4,Phase 2,Phase 3,Phase 1

118072-93-8

68740

Acetaminophen

Approved

Phase 4,Phase 2,Phase 1,Not Applicable

103-90-2

1983

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

50-18-0, 6055-19-2

2907

Proguanil

Approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

500-92-5

4923

Tocopherol

Approved, Investigational

Phase 4,Phase 3,Phase 2,Not Applicable

1406-66-2

14986

Sirolimus

Approved, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

53123-88-9

46835353 5284616 6436030

Everolimus

Approved

Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1

159351-69-6

70789204 6442177

chloroquine

Approved, Investigational, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1

54-05-7

2719

Ketamine

Approved, Vet_approved

Phase 4,Phase 3,Phase 2,Not Applicable

6740-88-1

3821

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4,Phase 1,Phase 2,Not Applicable

93-14-1

3516

Peginterferon alfa-2a

Approved, Investigational

Phase 4,Phase 2

198153-51-4

5360545

Ribavirin

Approved

Phase 4,Phase 3,Phase 2,Not Applicable

36791-04-5

37542

Epinephrine

Approved, Vet_approved

Phase 4

51-43-4

5816

Prilocaine

Approved

Phase 4

721-50-6

4906

Mannitol

Approved, Investigational

Phase 4,Phase 3

69-65-8

6251 453

Racepinephrine

Approved

Phase 4

329-65-7

838

Sodium Citrate

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

68-04-2

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4,Phase 2

437-38-7

3345

Zinc

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

7440-66-6

32051

Zinc sulfate

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

7733-02-0

Hydromorphone

Approved, Illicit

Phase 4,Phase 3,Phase 2,Not Applicable

466-99-9

5284570

Primaquine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

90-34-6

4908

Sofosbuvir

Approved

Phase 4,Phase 2

1190307-88-0

45375808

Velpatasvir

Approved, Investigational

Phase 4

1377049-84-7

67683363

Ledipasvir

Approved

Phase 4,Phase 2

1256388-51-8

67505836

Dapsone

Approved, Investigational

Phase 4,Phase 3

80-08-0

2955

Busulfan

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

55-98-1

2478

Tacrolimus

Approved, Investigational

Phase 4,Phase 2,Phase 1

104987-11-3

6473866 445643 439492

Fludarabine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

75607-67-9, 21679-14-1

30751

Amodiaquine

Approved, Investigational

Phase 4,Phase 1,Phase 2

86-42-0

2165

Sulfadoxine

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2

2447-57-6

17134

Pyrimethamine

Approved, Investigational, Vet_approved

Phase 4,Phase 3,Phase 1,Phase 2

58-14-0

4993

Warfarin

Approved

Phase 4,Phase 2,Phase 1,Not Applicable

81-81-2

54678486 6691

tannic acid

Approved

Phase 4,Phase 2,Phase 1,Not Applicable

1401-55-4

Benzocaine

Approved, Investigational

Phase 4,Phase 2,Phase 1,Not Applicable

1994-09-7, 94-09-7

2337

Codeine

Approved, Illicit

Phase 4,Phase 1,Phase 2

76-57-3

5284371

Metformin

Approved

Phase 4,Early Phase 1

657-24-9

14219 4091

Interventional clinical trials:

(show top 50) (show all 1103)

#	Name	Status	NCT ID	Phase	Drugs
1	Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency	Unknown status	NCT02594904	Phase 4	Yinzhihuang Oral Liquid
2	Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC	Unknown status	NCT01795794	Phase 4	omeprazole
3	Mobile-Directly Observed Therapy on Adherence to Hydroxyurea	Unknown status	NCT02844673	Phase 4	Hydroxyurea
4	B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals	Unknown status	NCT01846923	Phase 4
5	The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study	Unknown status	NCT01323608	Phase 4	Vitamin D3;Placebo
6	Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major	Unknown status	NCT00103753	Phase 4	deferiprone
7	Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major	Unknown status	NCT02342145	Phase 4	Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
8	Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin	Completed	NCT00491179	Phase 4	Pegylated interferon alfa-2a and ribavirin;Pegylated interferon alfa-2a and ribavirin
9	Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C	Completed	NCT00491244	Phase 4	Peginterferon alfa-2a and ribavirin;Peginterferon alfa-2a
10	A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection	Completed	NCT00353418	Phase 4	Peginterferon alfa-2a;Ribavirin;Ribavirin
11	Evaluation of Ureteral Patency in the Post-indigo Carmine Era	Completed	NCT02677623	Phase 4	Pyridium;Sodium Fluorescein;Mannitol
12	Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3	Completed	NCT00056862	Phase 4	Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
13	Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease	Completed	NCT00028093	Phase 4	Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
14	Long-Term Therapy With Ribavirin for Chronic Hepatitis C	Completed	NCT00001854	Phase 4	Ribavirin
15	Intranasal Fentanyl Versus Intravenous Morphine in the Treatment of Severe Painful Sickle Cell Crises in Children	Completed	NCT03682211	Phase 4	Fentanyl Citrate;Morphine sulphate
16	Zinc Supplementation on Cellular Immunity in Thalassemia Major	Completed	NCT03117192	Phase 4	Zinc Sulfate;Sucrose Syrup
17	Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions	Completed	NCT02731157	Phase 4	Rejuvesol
18	Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia	Completed	NCT01709838	Phase 4	ICL670 deferasirox
19	Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated	Completed	NCT01609192	Phase 4	Hydrea® (hydroxyurea )
20	Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis	Completed	NCT01482091	Phase 4	Fentanyl Citrate;Normal Saline
21	Efficacy Study of the Use of Sequential DFP-DFO Versus DFP	Completed	NCT00733811	Phase 4	Deferiprone (DFP) and Deferoxamine (DFO);Deferiprone (DFP)
22	Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events	Completed	NCT00346242	Phase 4	Zoledronic Acid
23	Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia	Completed	NCT03095326	Phase 4	Sucrose
24	Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)	Completed	NCT02522104	Phase 4	Siklos
25	Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease	Completed	NCT02222246	Phase 4	Hydromorphone (Standardized, weight-based dosing);Morphine Sulfate (Standardized, weight-based dosing);Hydromorphone (Patient Specific dosing);Morphine Sulfate (Patient Specific dosing)
26	An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)	Completed	NCT01736540	Phase 4
27	Post Hematopoietic Stem Cell Transplantation	Completed	NCT01610297	Phase 4	ICL670
28	Combo Chelation Trial	Completed	NCT00901199	Phase 4	Combo Chelation with Deferasirox (Exjade) and Desferal (DFO)
29	Pilot Study for Patients With Poor Response to Deferasirox	Completed	NCT00749515	Phase 4	Deferoxamine;Deferasirox
30	Safety and Tolerability of Low Dose Primaquine	Completed	NCT02434952	Phase 4	Dihydroartemisinin piperaquine (DHA PP);Primaquine
31	Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)	Completed	NCT00171301	Phase 4	Deferasirox
32	Efficacy Study in Removing Excess Iron From the Heart	Completed	NCT00105495	Phase 4	Ferriprox (deferiprone);Desferal (deferoxamine)
33	Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus	Completed	NCT03961828	Phase 4	Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]
34	Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major	Completed	NCT00800761	Phase 4	Deferoxamine and Deferiprone;Deferoxamine
35	Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial	Completed	NCT03032666	Phase 4	sofosbuvir/velpatasvir
36	This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.	Completed	NCT01250951	Phase 4	Deferasirox
37	Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency	Completed	NCT00243542	Phase 4	ACZONE Gel, 5%;Vehicle
38	Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection	Completed	NCT00707850	Phase 4	PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
39	Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload	Completed	NCT00564941	Phase 4	deferasirox
40	Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)	Completed	NCT00867932	Phase 4	Eculizumab
41	The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major	Recruiting	NCT02984475	Phase 4	Metformin
42	Colla Corii Asini Treating Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency)	Recruiting	NCT03374111	Phase 4	Colla corii asini;a Simulate Agent of Colla corii asini granule
43	Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?	Recruiting	NCT03541980	Phase 4	Acetaminophen;Normal saline
44	Study on the Mechanism of Colla Corri Asini in the Treatment of Thalassemia Patients With Pregnancy Anemia	Recruiting	NCT03392298	Phase 4	Colla corii asini
45	Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major	Recruiting	NCT03171831	Phase 4	Busulfan;Cyclophosphamide;Fludarabine;Mycophenolate mofetil;Tacrolimus;Methotrexate;Thymoglobulin;Basiliximab
46	Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children	Recruiting	NCT03591575	Phase 4	Deferiprone oral solution;Placebo
47	Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias	Recruiting	NCT02041299	Phase 4	Deferiprone;Deferoxamine
48	Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)	Recruiting	NCT03178643	Phase 4	Proguanil Oral Tablet;Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ);Dihydroartemisinin-Piperaquine (DP)
49	L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension	Recruiting	NCT03402191	Phase 4	L-arginine;Sildenafil
50	Contraception in Women With Sickle Cell Disease	Active, not recruiting	NCT02594462	Phase 4	etonogestrel-releasing implant contraceptive

Search NIH Clinical Center for Hemolytic Anemia

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :

alpha-tocopherol acetate

d-alpha-tocopheryl acetate

dl-alpha tocopheryl acetate

tocopherol acetate

tocopherol,dl-alpha

tocopherols

tocopheryl acid succinate

tocopheryl acid succinate,d-alpha

vitamin e

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Hemolytic Anemia cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Hemolytic Anemia:

Hematopoietic stem cell transplantation for the treatment of genetic blood cell-related diseases

Embryonic/Adult Cultured Cells Related to Hemolytic Anemia:

	Umbilical cord blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: anemia, hemolytic

Sources

Genetic Tests for Hemolytic Anemia

Genetic tests related to Hemolytic Anemia:

#	Genetic test	Affiliating Genes
1	Hemolytic Anemia ³⁰

Sources

Anatomical Context for Hemolytic Anemia

MalaCards organs/tissues related to Hemolytic Anemia:

⁴²

Bone, Bone Marrow, T Cells, Liver, Heart, Kidney, Testes

Sources

Publications for Hemolytic Anemia

Articles related to Hemolytic Anemia:

(show top 50) (show all 3346)

#	Title	Authors	Year
1	Etoricoxib-induced immune hemolytic anemia: first case presenting acute kidney failure. ( 30865300 )	Burgos Pratx L...Salamone H	2019
2	Severe hemolytic anemia due to combined α thalassemia and de novo Hemoglobin Sabine. ( 30673812 )	Chen X...Fu S	2019
3	Hot and Cold: A Concurrent Warm and Cold Autoimmune Hemolytic Anemia in B-cell Prolymphocytic Leukemia. ( 30947164 )	Feld J...Nahas M	2019
4	Hemolytic Anemia of Malignancy: A Case Study Involving Signet Ring Cell Metastatic Breast Cancer with Severe Microangiopathic Hemolytic Anemia. ( 31043946 )	Lee EH...Nagaraj G	2019
5	High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease. ( 30324459 )	Makishima K...Chiba S	2019
6	Severe congenital hemolytic anemia caused by a novel compound heterozygous PKLR gene mutation in a Chinese boy. ( 30628965 )	Liu PP...Liu T	2019
7	Aberrant splicing contributes to severe α-spectrin-linked congenital hemolytic anemia. ( 31038472 )	Gallagher PG...Schulz VP	2019
8	Refractory immune hemolytic anemia in an immunocompetent infant with cytomegalovirus infection. ( 31045313 )	Loureiro B...Kj?llerstr?m P	2019
9	Glucose Phosphate Isomerase Deficiency: High Prevalence of p.Arg347His Mutation in Indian Population Associated with Severe Hereditary Non-Spherocytic Hemolytic Anemia Coupled with Neurological Dysfunction. ( 31030358 )	Kedar PS...Madkaikar M	2019
10	Abdominal pain in combination with an unexplained hemolytic anemia are crucial signs to test for paroxysmal nocturnal hemoglobinuria: A case report. ( 30656036 )	Elias NS...Vermeer HJ	2019
11	Severe hemolytic anemia due to transient acquired G6PD deficiency after ingestion of sodium chlorite. ( 30231641 )	Hulshof PBJE...van Zwieten R	2019
12	A new onset of thrombocytopenia and microangiopathic hemolytic anemia in the healthcare setting: A challenge for diagnosis. ( 30264862 )	Di M...Butera JN	2019
13	Pertussis: An uncommon cause of microangiopathic hemolytic anemia in an infant. ( 30328133 )	Pryce A...Bain BJ	2019
14	Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. ( 30347480 )	Tanios GE...Munker R	2019
15	Delayed Hemolytic Anemia after Treatment with Artesunate: Case Report and Literature Review. ( 30411691 )	Salehi M...Khalili H	2019
16	Presumptive Glucocorticoid-Induced Refractory Hypocalcemia in a Dog with Idiopathic Immune-Mediated Hypoparathyroidism, Thrombocytopenia, and Hemolytic Anemia. ( 30427709 )	Jaffey J...Hyland J	2019
17	Vaccination and Associated Adverse Events in Dogs Previously Treated for Primary Immune-Mediated Hemolytic Anemia. ( 30427712 )	Moon A...Veir J	2019
18	Prognosis of autoimmune hemolytic anemia in critically ill patients. ( 30536106 )	Lafarge A...Mariotte E	2019
19	Autoimmune hemolytic anemia and immune thrombocytopenia following hematopoietic stem cell transplant: A critical review of the literature. ( 30537439 )	Neunert CE...Despotovic JM	2019
20	IgM-mediated Warm Autoimmune Hemolytic Anemia: An Autopsy Report. ( 30568122 )	Ito T...Takahara N	2019
21	An integration-free iPSC line (MUSIi008-A) derived from a patient with severe hemolytic anemia carrying compound heterozygote mutations in KLF1 gene for disease modeling. ( 30605837 )	Potirat P...Issaragrisil S	2019
22	Ceftriaxone-induced immune hemolytic anemia in a case with large vestibular aqueduct syndrome after cochlear implant. ( 30628967 )	Wang Y...Ying YQ	2019
23	Cold type autoimmune hemolytic anemia- a rare manifestation of infectious mononucleosis; serum ferritin as an important biomarker. ( 30658594 )	Dematapitiya C...Satharasinghe R	2019
24	The Case \| A 78-year-old woman with acute kidney injury and hemolytic anemia. ( 30665579 )	Zecher D...Zipfel PF	2019
25	Low-dose rituximab in autoimmune hemolytic anemia: 10 years after. ( 30670440 )	Fattizzo B...Barcellini W	2019
26	The first reported case of drug-induced hemolytic anemia caused by dimethyl fumarate in a patient with multiple sclerosis. ( 30702749 )	Quintanilla-Bord?s C...Mar?n M	2019
27	A Case of Pregnancy Complicated with Evans Syndrome with Sequential Development of Autoimmune Warm Antibody Hemolytic Anemia and Idiopathic Thrombocytopenic Purpura. ( 30733882 )	Suzuki H...Suginami K	2019
28	Immunosensor for the Diagnostics of Autoimmune Hemolytic Anemia (AIHA) Based on Immobilization of a Monoclonal Antibody on a Layer of Silk Fibroin. ( 30764933 )	Moraes ML...Ribeiro SJL	2019
29	Clinical and Laboratory Features of Autoimmune Hemolytic Anemia Associated with Immune Checkpoint Inhibitors. ( 30790338 )	Leaf RK...Leaf DE	2019
30	Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection. ( 30798587 )	Sato S...Yoshiji H	2019
31	ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats. ( 30806491 )	Garden OA...Szladovits B	2019
32	Transient appearance of ring sideroblasts in peripheral blood in the acute phase of secondary hemolytic anemia. ( 30819781 )	Wang F...Wang G	2019
33	Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer. ( 30828042 )	Okawa S...Shibayama T	2019
34	Autoimmune Hemolytic Anemia, Erythrophagocytosis and Liver Dysfunction After Cefixime Use for Urinary Tract Infection in a Child. ( 30828180 )	Kaya Z...Kalkan G	2019
35	Ceftriaxone-Induced Immune Hemolytic Anemia: In Vitro Reversal with Peptide Inhibitor of Complement C1 (PIC1). ( 30838143 )	Cunnion KM...Owen WC	2019
36	ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs. ( 30847984 )	Swann JW...Whitley NT	2019
37	Infantile Pyknocytosis: An Uncommon Cause of Newborn Hemolytic Anemia. ( 30933020 )	Castillo J...Mehta PS	2019
38	Autoimmune hemolytic anemia and ovarian dermoid cysts in pregnancy. ( 30957135 )	Felemban AA...Alsahabi JA	2019
39	The Case \| Microangiopathic hemolytic anemia in a young female. ( 31010484 )	Selvaskandan H...Iyasere O	2019
40	Cardiac Prostheses-Related Hemolytic Anemia. ( 31039274 )	Alkhouli M...Berzingi C	2019
41	Molecular diagnostic update in hereditary hemolytic anemia and neonatal hyperbilirubinemia. ( 31069991 )	Rets A...Agarwal AM	2019
42	B-cell depletion induces prolonged remission in patients with giant cell hepatitis and autoimmune hemolytic anemia. ( 31076361 )	Matarazzo L...Maggiore G	2019
43	A case series of pediatric patients with direct antiglobulin test negative autoimmune hemolytic anemia. ( 31111963 )	Miller J...Narla A	2019
44	Durable responses in refractory autoimmune hemolytic anemia with alemtuzumab. ( 29334337 )	McAlister RK...Reddy NM	2019
45	Molecular detection of Mycoplasma ovis in an outbreak of hemolytic anemia in sheep from Veracruz, Mexico. ( 29934796 )	Mart?nez-Hern?ndez JM...S?nchez-Montes S	2019
46	Ectopic expression of band 3 anion transport protein in colorectal cancer revealed in an autoimmune hemolytic anemia patient. ( 30063906 )	Kawamoto S...Takubo T	2019
47	Protective Role of Selenium Against Hemolytic Anemia Is Mediated Through Redox Modulation. ( 30151563 )	Kaur R...Kaushal N	2019
48	Autoimmune hemolytic anemia, autoimmune neutropenia and aplastic anemia in the elderly. ( 30527923 )	Barcellini W...Cortelezzi A	2018
49	Autoimmune Hemolytic Anemia Obscured by the Obstructive Jaundice Associated with IgG4-related Sclerosing Cholangitis in a Patient with Type 1 Autoimmune Pancreatitis: A Case Report and Review of the Literature. ( 29269682 )	Yoshida M...Joh T	2018
50	Acute Brucellosis Presenting as an Autoimmune Hemolytic Anemia. ( 30498608 )	Meena DS...Meena V	2018

Sources

Genes for Hemolytic Anemia

Genes related to Hemolytic Anemia (2 elite genes):

(show all 33)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	SPTB	Spectrin Beta, Erythrocytic	Protein Coding	462.16	Pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)	9005995
2	HBB	Hemoglobin Subunit Beta	Protein Coding	452.62	Pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Variants (show sections)	17854302 20215064 10228390 (more) 17003927 17467389 19527272 19603597
3	G6PD	Glucose-6-Phosphate Dehydrogenase	Protein Coding	66.12	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)	19494543 15645702 9332310 (more) 18677765 9674740 11849231 18177777 2049468 12187030 7947239 10571945 1807850 19198723 1536798 16204390 1805484 7889645 1697823 1733837 15906720 19705624 7825590 11042039 16753852 16212642 15235140 14973180 14757424 12737938 12476860 11221636 11271380 8090250 20065266 18852594 16088936 16079115 15738610 15079811 12704264 10698963 11934348 12041544 10747271 7858267 7932916 1283668 17726510 17729111 10666231 18343605 17365988 14647867 14641141 9290617 8629088 7489710 8090251 8081534 19904460 20007901 8273193 8436389 2019023 20085579 20426517 17385678 16680190 12367588 7873396 1894717 1868914 18823322 15621740 11916749 10359058 10352334 15542105 11842483 11400794 10157546 7602782 1337501 1895921 1999409 2222408 2157298 10522135 8890580 7655862 7947281 1879833 17623517 16443279 16522554 10916676 8111051 2195189 15598086
4	GPI	Glucose-6-Phosphate Isomerase	Protein Coding	62.21	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)	9362562 11371164 8417789 (more) 9856489 9266190 8822952 7989588 8822954 15949716 2115718 12737943 17041899 2267195 10916680 9446754
5	NT5C3A	5'-Nucleotidase, Cytosolic IIIA	Protein Coding	62.19	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)	16522554 10942414 16956825 (more) 11369620
6	PKLR	Pyruvate Kinase L/R	Protein Coding	58.5	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries (show sections)	2019023 17550844 15870173 (more) 10679942 19755962 15059150 17547515 7948315 9827908 8161797
7	CD59	CD59 Molecule (CD59 Blood Group)	Protein Coding	57.86	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)	11986227 11930678
8	GCLC	Glutamate-Cysteine Ligase Catalytic Subunit	Protein Coding	54.71	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)	18024385 10733484
9	SLC4A1	Solute Carrier Family 4 Member 1 (Diego Blood Group)	Protein Coding	54.46	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Variants (show sections)	11208088 9854053 17554061 (more) 9306337 15067510 17056673 18266205 11160790
10	AK1	Adenylate Kinase 1	Protein Coding	52.6	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
11	RHAG	Rh Associated Glycoprotein	Protein Coding	52.28	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Summaries Variants (show sections)	19807729 9442063
12	HK1	Hexokinase 1	Protein Coding	49.93	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
13	PGK1	Phosphoglycerate Kinase 1	Protein Coding	49.09	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries (show sections)	16857429 12956773
14	ALDOA	Aldolase, Fructose-Bisphosphate A	Protein Coding	48.22	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Summaries (show sections)	2229018 14766013 1433940 (more) 15632214
15	GSS	Glutathione Synthetase	Protein Coding	47.64	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Variants (show sections)	8896573 16435214 8634459 (more) 9679548 17397529
16	ADAMTS13	ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13	Protein Coding	43.9	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications (show sections)	12923683 15524133
17	SPTA1	Spectrin Alpha, Erythrocytic 1	Protein Coding	43.65	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
18	EPB42	Erythrocyte Membrane Protein Band 4.2	Protein Coding	43.13	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries (show sections)
19	ANK1	Ankyrin 1	Protein Coding	42.2	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications (show sections)	9235914
20	PIGA	Phosphatidylinositol Glycan Anchor Biosynthesis Class A	Protein Coding	41.9	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications (show sections)	17124035
21	PIEZO1	Piezo Type Mechanosensitive Ion Channel Component 1	Protein Coding	31.62	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
22	HBA2	Hemoglobin Subunit Alpha 2	Protein Coding	29.68	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications (show sections)	7994622 17716993 7856931
23	ATP11C	ATPase Phospholipid Transporting 11C	Protein Coding	29.43	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Variants (show sections)
24	TPI1	Triosephosphate Isomerase 1	Protein Coding	28.66	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications (show sections)	10699493 1959537 8244340 (more) 10782327 12023819 14559119 8503454 2339591 7901638 8944178 18458110 9850739
25	HP	Haptoglobin	Protein Coding	24.23	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	17974404 7955584 1795445 (more) 1726769 9177009 19340395 11746180 16760505 17338432 16183409 8925755 12023180 8890570 11399734 12006477
26	STOM	Stomatin	Protein Coding	22.72	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Summaries (show sections)	18182167 9147127 15611110
27	CFI	Complement Factor I	Protein Coding	22.37	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Summaries (show sections)
28	CD46	CD46 Molecule	Protein Coding	22.24	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Variants (show sections)
29	HBA1	Hemoglobin Subunit Alpha 1	Protein Coding	22.15	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
30	PRDX2	Peroxiredoxin 2	Protein Coding	22.08	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Summaries (show sections)
31	C3	Complement C3	Protein Coding	21.79	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Variants (show sections)
32	HBG2	Hemoglobin Subunit Gamma 2	Protein Coding	20.94	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	12006477 16132702 14654534
33	CFH	Complement Factor H	Protein Coding	20.54	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders (show sections)	10544747 17000000 18371543

Sources

Variations for Hemolytic Anemia

ClinVar genetic disease variations for Hemolytic Anemia:

⁶ (show top 50) (show all 140)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	HBB	NM_000518.5(HBB): c.127T> C (p.Phe43Leu)	single nucleotide variant	Pathogenic	rs33924146	GRCh38	Chromosome 11, 5226765: 5226765
2	HBB	NM_000518.5(HBB): c.127T> C (p.Phe43Leu)	single nucleotide variant	Pathogenic	rs33924146	GRCh37	Chromosome 11, 5247995: 5247995
3	HBB	NM_000518.4(HBB): c.127T> G (p.Phe43Val)	single nucleotide variant	Pathogenic	rs33924146	GRCh37	Chromosome 11, 5247995: 5247995
4	HBB	NM_000518.4(HBB): c.127T> G (p.Phe43Val)	single nucleotide variant	Pathogenic	rs33924146	GRCh38	Chromosome 11, 5226765: 5226765
5	SLC4A1	NM_000342.3(SLC4A1): c.166A> G (p.Lys56Glu)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs5036	GRCh37	Chromosome 17, 42338945: 42338945
6	SLC4A1	NM_000342.3(SLC4A1): c.166A> G (p.Lys56Glu)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs5036	GRCh38	Chromosome 17, 44261577: 44261577
7	SLC4A1	NM_000342.3(SLC4A1): c.118G> A (p.Glu40Lys)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs45562031	GRCh37	Chromosome 17, 42338993: 42338993
8	SLC4A1	NM_000342.3(SLC4A1): c.118G> A (p.Glu40Lys)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs45562031	GRCh38	Chromosome 17, 44261625: 44261625
9	SLC4A1	NM_000342.3(SLC4A1): c.2561C> T (p.Pro854Leu)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs2285644	GRCh37	Chromosome 17, 42328621: 42328621
10	SLC4A1	NM_000342.3(SLC4A1): c.2561C> T (p.Pro854Leu)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs2285644	GRCh38	Chromosome 17, 44251253: 44251253
11	SLC4A1	NM_000342.3(SLC4A1): c.2701C> T (p.Arg901Trp)	single nucleotide variant	Uncertain significance	rs201265160	GRCh37	Chromosome 17, 42327861: 42327861
12	SLC4A1	NM_000342.3(SLC4A1): c.2701C> T (p.Arg901Trp)	single nucleotide variant	Uncertain significance	rs201265160	GRCh38	Chromosome 17, 44250493: 44250493
13	SLC4A1	NM_000342.3(SLC4A1): c.2712C> T (p.Tyr904=)	single nucleotide variant	Benign/Likely benign	rs45519733	GRCh37	Chromosome 17, 42327850: 42327850
14	SLC4A1	NM_000342.3(SLC4A1): c.2712C> T (p.Tyr904=)	single nucleotide variant	Benign/Likely benign	rs45519733	GRCh38	Chromosome 17, 44250482: 44250482
15	SLC4A1	NM_000342.3(SLC4A1): c.2688T> C (p.Asp896=)	single nucleotide variant	Benign/Likely benign	rs45497993	GRCh37	Chromosome 17, 42327874: 42327874
16	SLC4A1	NM_000342.3(SLC4A1): c.2688T> C (p.Asp896=)	single nucleotide variant	Benign/Likely benign	rs45497993	GRCh38	Chromosome 17, 44250506: 44250506
17	SLC4A1	NM_000342.3(SLC4A1): c.2584G> A (p.Val862Ile)	single nucleotide variant	Benign/Likely benign	rs5026	GRCh37	Chromosome 17, 42328598: 42328598
18	SLC4A1	NM_000342.3(SLC4A1): c.2584G> A (p.Val862Ile)	single nucleotide variant	Benign/Likely benign	rs5026	GRCh38	Chromosome 17, 44251230: 44251230
19	SLC4A1	NM_000342.3(SLC4A1): c.1953C> T (p.His651=)	single nucleotide variant	Benign/Likely benign	rs5021	GRCh37	Chromosome 17, 42331968: 42331968
20	SLC4A1	NM_000342.3(SLC4A1): c.1953C> T (p.His651=)	single nucleotide variant	Benign/Likely benign	rs5021	GRCh38	Chromosome 17, 44254600: 44254600
21	SLC4A1	NM_000342.3(SLC4A1): c.1770G> A (p.Lys590=)	single nucleotide variant	Benign/Likely benign	rs35807245	GRCh38	Chromosome 17, 44255703: 44255703
22	SLC4A1	NM_000342.3(SLC4A1): c.1770G> A (p.Lys590=)	single nucleotide variant	Benign/Likely benign	rs35807245	GRCh37	Chromosome 17, 42333071: 42333071
23	SLC4A1	NM_000342.3(SLC4A1): c.1323G> A (p.Leu441=)	single nucleotide variant	Benign/Likely benign	rs5017	GRCh37	Chromosome 17, 42335135: 42335135
24	SLC4A1	NM_000342.3(SLC4A1): c.1323G> A (p.Leu441=)	single nucleotide variant	Benign/Likely benign	rs5017	GRCh38	Chromosome 17, 44257767: 44257767
25	SLC4A1	NM_000342.3(SLC4A1): c.1249C> T (p.Leu417=)	single nucleotide variant	Benign/Likely benign	rs5015	GRCh37	Chromosome 17, 42335387: 42335387
26	SLC4A1	NM_000342.3(SLC4A1): c.1249C> T (p.Leu417=)	single nucleotide variant	Benign/Likely benign	rs5015	GRCh38	Chromosome 17, 44258019: 44258019
27	SLC4A1	NM_000342.3(SLC4A1): c.924G> A (p.Leu308=)	single nucleotide variant	Benign/Likely benign	rs5013	GRCh37	Chromosome 17, 42335944: 42335944
28	SLC4A1	NM_000342.3(SLC4A1): c.924G> A (p.Leu308=)	single nucleotide variant	Benign/Likely benign	rs5013	GRCh38	Chromosome 17, 44258576: 44258576
29	SLC4A1	NM_000342.3(SLC4A1): c.113A> C (p.Asp38Ala)	single nucleotide variant	Benign/Likely benign	rs5035	GRCh37	Chromosome 17, 42338998: 42338998
30	SLC4A1	NM_000342.3(SLC4A1): c.113A> C (p.Asp38Ala)	single nucleotide variant	Benign/Likely benign	rs5035	GRCh38	Chromosome 17, 44261630: 44261630
31	SLC4A1	NM_000342.3(SLC4A1): c.16-14G> A	single nucleotide variant	Benign/Likely benign	rs145502796	GRCh38	Chromosome 17, 44262740: 44262740
32	SLC4A1	NM_000342.3(SLC4A1): c.16-14G> A	single nucleotide variant	Benign/Likely benign	rs145502796	GRCh37	Chromosome 17, 42340108: 42340108
33	SLC4A1	NM_000342.3(SLC4A1): c.*1832G> A	single nucleotide variant	Uncertain significance	rs886052988	GRCh37	Chromosome 17, 42325994: 42325994
34	SLC4A1	NM_000342.3(SLC4A1): c.*1832G> A	single nucleotide variant	Uncertain significance	rs886052988	GRCh38	Chromosome 17, 44248626: 44248626
35	SLC4A1	NM_000342.3(SLC4A1): c.*1721G> A	single nucleotide variant	Likely benign	rs62078947	GRCh37	Chromosome 17, 42326105: 42326105
36	SLC4A1	NM_000342.3(SLC4A1): c.*1721G> A	single nucleotide variant	Likely benign	rs62078947	GRCh38	Chromosome 17, 44248737: 44248737
37	SLC4A1	NM_000342.3(SLC4A1): c.*1676A> G	single nucleotide variant	Uncertain significance	rs745898810	GRCh37	Chromosome 17, 42326150: 42326150
38	SLC4A1	NM_000342.3(SLC4A1): c.*1676A> G	single nucleotide variant	Uncertain significance	rs745898810	GRCh38	Chromosome 17, 44248782: 44248782
39	SLC4A1	NM_000342.3(SLC4A1): c.1606_1608dupAAA	duplication	Uncertain significance	rs57466226	GRCh37	Chromosome 17, 42326218: 42326220
40	SLC4A1	NM_000342.3(SLC4A1): c.1606_1608dupAAA	duplication	Uncertain significance	rs57466226	GRCh38	Chromosome 17, 44248850: 44248852
41	SLC4A1	NM_000342.3(SLC4A1): c.*1608delA	deletion	Uncertain significance	rs57466226	GRCh37	Chromosome 17, 42326218: 42326218
42	SLC4A1	NM_000342.3(SLC4A1): c.*1608delA	deletion	Uncertain significance	rs57466226	GRCh38	Chromosome 17, 44248850: 44248850
43	SLC4A1	NM_000342.3(SLC4A1): c.*1198A> T	single nucleotide variant	Uncertain significance	rs886052992	GRCh38	Chromosome 17, 44249260: 44249260
44	SLC4A1	NM_000342.3(SLC4A1): c.*1198A> T	single nucleotide variant	Uncertain significance	rs886052992	GRCh37	Chromosome 17, 42326628: 42326628
45	SLC4A1	NM_000342.3(SLC4A1): c.*897G> A	single nucleotide variant	Likely benign	rs5030	GRCh38	Chromosome 17, 44249561: 44249561
46	SLC4A1	NM_000342.3(SLC4A1): c.*897G> A	single nucleotide variant	Likely benign	rs5030	GRCh37	Chromosome 17, 42326929: 42326929
47	SLC4A1	NM_000342.3(SLC4A1): c.2210C> T (p.Ala737Val)	single nucleotide variant	Uncertain significance	rs886052997	GRCh38	Chromosome 17, 44253219: 44253219
48	SLC4A1	NM_000342.3(SLC4A1): c.2210C> T (p.Ala737Val)	single nucleotide variant	Uncertain significance	rs886052997	GRCh37	Chromosome 17, 42330587: 42330587
49	SLC4A1	NM_000342.3(SLC4A1): c.1637A> G (p.Asp546Gly)	single nucleotide variant	Uncertain significance	rs886052998	GRCh38	Chromosome 17, 44255836: 44255836
50	SLC4A1	NM_000342.3(SLC4A1): c.1637A> G (p.Asp546Gly)	single nucleotide variant	Uncertain significance	rs886052998	GRCh37	Chromosome 17, 42333204: 42333204

Sources

Expression for Hemolytic Anemia

Search GEO for disease gene expression data for Hemolytic Anemia.

Sources

Pathways for Hemolytic Anemia

Pathways related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 15)

#	Super pathways	Score	Top Affiliating Genes
1	Metabolism ⁶⁷ Show member pathways Metabolic pathways ³⁸ Metabolism of lipids and lipoproteins ⁶⁷	13.75	AK1 ALDOA G6PD GCLC GPI GSS
2	Glycosaminoglycan metabolism ⁶⁷ Show member pathways chondroitin sulfate biosynthesis ¹ chondroitin sulfate biosynthesis (late stages) ¹ Heparan sulfate/heparin (HS-GAG) metabolism ⁶⁷ HS-GAG biosynthesis ⁶⁷ Hyaluronan biosynthesis and export ⁶⁷ Hyaluronan metabolism ⁶⁷ Hyaluronan uptake and degradation ⁶⁷ Metabolism of carbohydrates ⁶⁷	12.66	ALDOA G6PD GPI HK1 PGK1 PKLR
3	Glucose metabolism ⁶⁷ Show member pathways gluconeogenesis ¹ Gluconeogenesis ⁶⁷ glycogen biosynthesis ¹ Glycogen breakdown (glycogenolysis) ⁶⁷ Glycogen storage disease type 0 (liver GYS2) ⁶⁷ Glycogen storage disease type II (GAA) ⁶⁷ Glycogen storage disease type IV (GBE1) ⁶⁷ Glycogen synthesis ⁶⁷ glycolysis ¹ Glycolysis ⁶⁷ Glycolysis / Gluconeogenesis ³⁸ Glycolysis and Gluconeogenesis ¹ Glycolysis and gluconeogenesis (short map) ²³ Lysosomal glycogen catabolism ⁶⁷ malate-aspartate shuttle ¹	12.44	ALDOA GPI HK1 PGK1 PKLR
4	Glucose / Energy Metabolism ⁴	12.33	ALDOA G6PD HBB HK1
5	L1CAM interactions ⁶⁷ Show member pathways CHL1 interactions ⁶⁷ Neurofascin interactions ⁶⁷ NrCAM interactions ⁶⁷	11.82	ANK1 SPTA1 SPTB
6	Carbon metabolism ³⁸ Show member pathways 2-Oxocarboxylic acid metabolism ³⁸ Biosynthesis of amino acids ³⁸ formaldehyde oxidation ¹	11.76	ALDOA G6PD GPI HK1 PGK1 PKLR
7	HIF-1 signaling pathway ³⁸	11.7	ALDOA HK1 PGK1
8	Citrate cycle (TCA cycle) ³⁸ Show member pathways pyruvate decarboxylation to acetyl CoA ¹ superpathway of conversion of glucose to acetyl CoA and entry into the TCA cycle ¹ TCA cycle ¹ TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc) ¹	11.64	ALDOA HK1 PGK1 PKLR
9	HIF-1-alpha transcription factor network ¹	11.48	ALDOA HK1 PGK1
10	Pentose phosphate pathway ³⁸ ¹ ¹ Show member pathways 5-Phosphoribose 1-diphosphate biosynthesis ⁶⁷ Insulin effects increased synthesis of Xylulose-5-Phosphate ⁶⁷ Pentose phosphate pathway (hexose monophosphate shunt) ⁶⁷ pentose phosphate pathway (non-oxidative branch) ¹ pentose phosphate pathway (oxidative branch) ¹ PRPP biosynthesis ¹	11.47	ALDOA G6PD GPI
11	Erythrocytes take up carbon dioxide and release oxygen ⁶⁷ Show member pathways Erythrocytes take up oxygen and release carbon dioxide ⁶⁷ O2/CO2 exchange in erythrocytes ⁶⁷	11.12	HBB RHAG SLC4A1
12	Interaction between L1 and Ankyrins ⁶⁷	11.02	ANK1 SPTA1 SPTB
13	Abacavir Pathway, Pharmacokinetics/Pharmacodynamics ⁶² Show member pathways adenine and adenosine salvage II ¹	10.66	PGK1 PKLR
14	Cori Cycle ¹	10.13	G6PD GPI HK1 PGK1
15	Pentose Phosphate Pathway (Erythrocyte), Pharmacodynamics ⁶²	10.11	G6PD GPI HK1

Sources

GO Terms for Hemolytic Anemia

Cellular components related to Hemolytic Anemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular exosome	GO:0070062	9.96	AK1 ALDOA CD59 G6PD GPI GSS
2	ficolin-1-rich granule lumen	GO:1904813	9.61	ALDOA GPI HBB
3	cytoplasmic side of plasma membrane	GO:0009898	9.5	ANK1 G6PD SPTA1
4	spectrin	GO:0008091	9.4	SPTA1 SPTB
5	intrinsic component of the cytoplasmic side of the plasma membrane	GO:0031235	9.37	SPTA1 SPTB
6	cortical cytoskeleton	GO:0030863	9.13	EPB42 SLC4A1 SPTA1
7	spectrin-associated cytoskeleton	GO:0014731	8.8	ANK1 SPTA1 SPTB
8	cytosol	GO:0005829	10	AK1 ALDOA ANK1 G6PD GCLC GPI

Biological processes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 16)

#	Name	GO ID	Score	Top Affiliating Genes
1	carbohydrate metabolic process	GO:0005975	9.76	G6PD GPI HK1 PKLR
2	regulation of cell shape	GO:0008360	9.73	ALDOA EPB42 SPTA1
3	ER to Golgi vesicle-mediated transport	GO:0006888	9.73	ANK1 CD59 SPTA1 SPTB
4	actin filament capping	GO:0051693	9.54	SPTA1 SPTB
5	gluconeogenesis	GO:0006094	9.54	ALDOA GPI PGK1
6	regulation of blood vessel size	GO:0050880	9.52	GCLC HBB
7	glutathione biosynthetic process	GO:0006750	9.51	GCLC GSS
8	bicarbonate transport	GO:0015701	9.5	HBB RHAG SLC4A1
9	erythrocyte maturation	GO:0043249	9.49	EPB42 G6PD
10	response to xenobiotic stimulus	GO:0009410	9.48	GCLC GSS
11	response to cadmium ion	GO:0046686	9.43	GCLC GPI GSS
12	cellular ion homeostasis	GO:0006873	9.4	RHAG SLC4A1
13	glycolytic process	GO:0006096	9.35	ALDOA GPI HK1 PGK1 PKLR
14	glucose 6-phosphate metabolic process	GO:0051156	9.33	G6PD GPI HK1
15	muscle cell cellular homeostasis	GO:0046716	9.25	ALDOA
16	canonical glycolysis	GO:0061621	9.02	ALDOA GPI HK1 PGK1 PKLR

Molecular functions related to Hemolytic Anemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	ATP binding	GO:0005524	9.87	AK1 EPB42 GCLC GSS HK1 PGK1
2	catalytic activity	GO:0003824	9.67	ALDOA GCLC HK1 PKLR
3	magnesium ion binding	GO:0000287	9.46	GCLC GSS NT5C3A PKLR
4	glucose binding	GO:0005536	9.26	G6PD HK1
5	structural constituent of cytoskeleton	GO:0005200	9.26	ANK1 EPB42 SPTA1 SPTB
6	ankyrin binding	GO:0030506	8.8	RHAG SLC4A1 SPTB

Sources

Sources for Hemolytic Anemia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷

Hemolytic Anemia

Aliases & Classifications for Hemolytic Anemia

MalaCards integrated aliases for Hemolytic Anemia:

Classifications:

External Ids:

Summaries for Hemolytic Anemia

Related Diseases for Hemolytic Anemia

Diseases in the Hemolytic Anemia family:

Diseases related to Hemolytic Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Hemolytic Anemia:

Symptoms & Phenotypes for Hemolytic Anemia

UMLS symptoms related to Hemolytic Anemia:

GenomeRNAi Phenotypes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Hemolytic Anemia:

Drugs & Therapeutics for Hemolytic Anemia

PubMedHealth treatment related to Hemolytic Anemia: 64

Drugs for Hemolytic Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 74 / NDF-RT 52 :

Cell-based therapeutics:

Cochrane evidence based reviews: anemia, hemolytic

Genetic Tests for Hemolytic Anemia

Genetic tests related to Hemolytic Anemia:

Anatomical Context for Hemolytic Anemia

MalaCards organs/tissues related to Hemolytic Anemia:

Publications for Hemolytic Anemia

Articles related to Hemolytic Anemia:

Genes for Hemolytic Anemia

Genes related to Hemolytic Anemia (2 elite genes):

Variations for Hemolytic Anemia

ClinVar genetic disease variations for Hemolytic Anemia:

Expression for Hemolytic Anemia

Pathways for Hemolytic Anemia

Pathways related to Hemolytic Anemia according to GeneCards Suite gene sharing:

GO Terms for Hemolytic Anemia

Cellular components related to Hemolytic Anemia according to GeneCards Suite gene sharing:

Biological processes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

Molecular functions related to Hemolytic Anemia according to GeneCards Suite gene sharing:

Sources for Hemolytic Anemia

PubMedHealth treatment related to Hemolytic Anemia: ⁶⁴

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :